Novartis said its studies show that Cosentyx (secukinumab), formulated to treat psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), achieves clearer skin in subjects after 12 weeks compared to Stelara (ustekinumab).

Modernizing Medicine to Showcase Enhanced EMR including Tools to Improve Patient Engagement and Support Price Transparency and at HIMSS19

Clinical trial released after nearly 1,000 people participated

For men and women living with sexual dysfunction, the physicians at Tennessee Urology provide safe and effective new therapies designed to restore sexual function and quality of life.

CirrusMD, the market leader in chat-first virtual care delivery, today announced its new collaboration with Sanitas Medical Centers.

People living with anxiety, depression or insomnia are being encouraged to look at cranial electrotherapy stimulation as a way to manage their condition.

Abelson Taylor and The Bloc are sponsoring the fifth annual Young Globals Student Competition & Internship, which will introduce students from design and technology institutions to careers in health care communications.

Innovative Technology Strengthens the Company's Comprehensive Knee Portfolio

Cleveland-based startup hires new CEO and prepares for market clearance

Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

A Statement from the National Kidney Foundation (NKF)

New findings from an international research team led by psychiatrists at NYU School of Medicine show that a newly-developed analytic model can predict soon after a shocking or scary event – and with significant accuracy -- the likelihood of someone developing Post-Traumatic Stress Disorder (PTSD).

JDRF, formerly known as the Juvenile Diabetes Research Foundation, is advising adults living with diabetes of the benefits of inhaling insulin close to, or even during, meal times.

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.

Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, announced the closing of a $65 million Series B financing. Proceeds will be used to advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors.

Risk greatest in people with later-stage cancers and lung and colon cancers

JHL Biotech announced that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL).

Compared to taking multiple injections daily, inhaled insulin can provide short-term benefits like controlling blood sugars after meal times.

MetTel is helping Rotech Healthcare Inc. to drive better patient care and personalization at healthcare facilities and at home through an innovative mobile initiative that has raised Rotech’s workforce productivity and doubled customer contact, both companies announced.